Shpakova A P, Bulycheva T I, Liubimova L S, Mendeleeva L P
Ter Arkh. 2000;72(11):62-7.
To characterize mixed lymphocyte culture (MLC) reaction used for determination of donor-recipient compatibility before bone marrow transplantation to patients with hematological malignancies and to assess the reaction significance.
The analysis was made of compatibility testing in MLC standard reaction performed in 134 patients with hematological malignancies with HLA-A, -B identical donors-sibs and in 5 patients with haploid identical donors.
Out of 134 patients, 22(91%) appeared compatible to donor sibs in MLC reaction, 12(9%) patients were incompatible. Mean RR for MLC-compatible couples made up: in RvD direction 77 +/- 0.17%, DvR 2.61 +/- 0.32%. 93% of RR values ranged from +15 to -15%, the rest--from +25% to -25%. Bone marrow transplantation was made in 83 patients. Graft retention was observed in 77(93%) patients. Acute and chronic graft versus host reaction developed in 15 and 17 patients, respectively.
An optimal protocol is proposed for examination of compatibility donor-recipient in MLC reaction in patients with hematological malignancies. It is intended for allogenic bone marrow transplantation in hematological departments.
对用于血液系统恶性肿瘤患者骨髓移植前供受者相容性测定的混合淋巴细胞培养(MLC)反应进行特征描述,并评估该反应的意义。
对134例血液系统恶性肿瘤患者与HLA - A、- B位点相同的同胞供者以及5例单倍体相同供者进行的MLC标准反应中的相容性检测进行分析。
134例患者中,22例(91%)在MLC反应中与同胞供者相容,12例(9%)患者不相容。MLC相容配对的平均RR值为:RvD方向77±0.17%,DvR方向2.61±0.32%。93%的RR值在+15%至 - 15%之间,其余在+25%至 - 25%之间。83例患者进行了骨髓移植。77例(93%)患者观察到移植物留存。分别有15例和17例患者发生了急性和慢性移植物抗宿主反应。
提出了一种用于检测血液系统恶性肿瘤患者MLC反应中供受者相容性的最佳方案。该方案适用于血液科的异体骨髓移植。